Long-acting injectable antipsychotics did not begin with the modern atypicals. The first widely used depot was fluphenazine decanoate, introduced in the 1960s and still on formularies in nearly every country in the world. It is cheap, well-understood, and for some patients remarkably effective. It also carries the side effect profile of a first-generation antipsychotic, which is the central tradeoff to discuss before starting it.
Fluphenazine decanoate is a long-acting injectable form of the first-generation antipsychotic fluphenazine, given roughly every two to four weeks, with strong efficacy on positive symptoms and a higher risk of movement-related side effects than newer options.
What it is
Fluphenazine is a high-potency phenothiazine antipsychotic, FDA-approved decades ago. The decanoate is an oily ester formulation that is injected intramuscularly; once in the muscle, the ester is slowly cleaved, releasing fluphenazine into circulation over two to four weeks. The product was historically marketed as Prolixin Decanoate in the United States; today it is more commonly dispensed as a generic.
Who it might be a fit for
- People who responded well to oral fluphenazine in the past
- People for whom cost is a major barrier — fluphenazine decanoate is among the cheapest LAIs available
- People with predominantly positive symptoms (hallucinations, delusions) and a history of nonadherence
- Settings where newer LAIs are not consistently stocked or affordable
Dosing in practice
Doses are individualised. Per FDA labelling and clinical practice, typical maintenance is in the range of 12.5 to 50 mg every two to three weeks, with some patients requiring more or less. A common starting strategy is a small test dose to confirm tolerance, followed by a maintenance regimen titrated against symptoms and side effects. Because the half-life of the depot is long, dose changes take weeks to fully express themselves — patience is essential.
Oral fluphenazine is sometimes continued for the first week or two after the initial injection until depot levels build up. Specifics vary by prescriber and previous oral exposure.
Side effects: the central conversation
The key tradeoff with any first-generation LAI is the rate of extrapyramidal symptoms (EPS) — drug-induced movement problems. These include:
- Acute dystonia — sudden muscle spasms, usually in the first days; often treatable with anticholinergics
- Parkinsonism — tremor, stiffness, slowed movement; see our EPS guide
- Akathisia — inner restlessness, an urge to keep moving
- Tardive dyskinesia — involuntary movements that can be permanent; risk increases with cumulative exposure
Fluphenazine carries a meaningfully higher risk of these effects than second-generation LAIs like Aristada, Invega Sustenna, or Risperdal Consta. Many patients who tolerate fluphenazine do well; others need to switch.
Other notable effects:
- Hyperprolactinemia — sexual side effects, breast changes; see our prolactin guide
- Sedation — typically less than chlorpromazine but still present
- Orthostatic hypotension
- QT prolongation — usually mild but worth knowing about
You develop high fever with muscle rigidity and confusion (possible neuroleptic malignant syndrome), severe muscle spasms in the neck or face (acute dystonia), or any new, persistent involuntary movements of the tongue, face, or limbs.
What the evidence shows
Long-term studies and meta-analyses, including a Cochrane review of fluphenazine decanoate, find it effective at preventing relapse compared with placebo, and broadly comparable in efficacy to other first-generation LAIs. Compared with second-generation LAIs, fluphenazine generally shows similar effects on positive symptoms but more EPS and less benefit on negative and cognitive symptoms.
The UK NICE guideline on schizophrenia (CG178) recommends LAIs broadly when adherence is a clinical priority, leaving the choice between first- and second-generation options to a shared decision between patient and prescriber.
Monitoring
- Baseline and ongoing assessment for involuntary movements — clinicians often use the AIMS (Abnormal Involuntary Movement Scale) every 6 months
- Prolactin level — particularly if symptoms (sexual changes, galactorrhoea, menstrual changes) appear
- ECG for QT prolongation if there are cardiac risk factors or interacting medications
- Metabolic labs — generally less of an issue than with second-generation antipsychotics, but still worth periodic checks
Why some clinicians still choose fluphenazine
- It is inexpensive and globally available
- For patients who responded well to oral fluphenazine, switching to the depot is straightforward
- Some patients tolerate fluphenazine better than they tolerate metabolic side effects of newer agents
- For very treatment-resistant patients, the additional dopamine blockade can be useful
Why some choose alternatives
- Higher rates of EPS and tardive dyskinesia compared with second-generation LAIs
- Limited benefit on negative and cognitive symptoms
- More frequent dosing intervals (every 2–4 weeks) than newer long-interval options like Invega Trinza
Talking to your prescriber
Useful questions before starting fluphenazine decanoate:
- Why this medication rather than a second-generation LAI?
- What's our plan for monitoring movement side effects over months and years?
- If I develop EPS, what's the management plan — dose reduction, anticholinergic, switch?
- How often will I need an AIMS assessment?
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed sources. Always consult your prescribing clinician before starting, stopping, or changing any medication.